Acutus Medical (AFIB) AI Stock Analysis

• Market Cap: $1.23M
• Dividend Yield: N/A
• Average Volume (3M): 27.96K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.14
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 85
• Sector: Healthcare
• Sector Strength: 60
• Industry: Medical - Devices
• EPS (TTM): -0.04
• Shares Outstanding: 29,912,306
• 10 Day Avg. Volume: 27,246
• 30 Day Avg. Volume: 27,957
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 19.07
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -7.46
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Acutus Medical's overall stock score reflects substantial financial difficulties, characterized by negative profitability, high leverage, and insolvency risks. Technical indicators suggest weak momentum, and valuation metrics are unfavorable due to ongoing losses. Strategic improvements are necessary to achieve financial stability.

Acutus Medical Business Overview & Revenue Model

Company Description

Acutus Medical, Inc. (AFIB) is a medical technology company that specializes in the development and commercialization of innovative solutions designed to improve the treatment of complex cardiac arrhythmias. Operating primarily in the healthcare sector, Acutus Medical focuses on providing electrophysiologists with advanced tools and technologies, such as its AcQMap system, which offers a comprehensive approach to mapping and treating atrial fibrillation and other arrhythmias.

How the Company Makes Money

Acutus Medical generates revenue through the sale and leasing of its medical devices, primarily the AcQMap system. The company's revenue model includes direct sales to hospitals and healthcare facilities, as well as partnerships with distributors and strategic alliances that enable broader market penetration. Acutus may also derive income from recurring revenue streams such as disposables and accessories associated with its mapping and treatment systems. Additionally, the company could benefit from collaborations with research institutions and other entities focused on advancing cardiac care technologies.

Acutus Medical Financial Statement Overview

Summary

Acutus Medical faces substantial financial challenges, characterized by declining revenues, high leverage, negative equity, and poor cash flow generation. The company's financial health is concerning, with ongoing losses and limited growth prospects.

Income Statement

Acutus Medical's revenue has declined significantly over the years, with a negative net income and consistently poor profit margins. The gross profit margin is slightly positive in the latest TTM, but the net profit margin remains negative, indicating ongoing profitability challenges.

Balance Sheet

The company's balance sheet is weak, with negative stockholders' equity and a high debt-to-equity ratio, reflecting significant leverage. The equity ratio is unfavorable, indicating potential financial instability.

Cash Flow

Acutus Medical shows negative free cash flow and operating cash flow, although there's a reduction in free cash flow negativity in the latest TTM. The company struggles with cash generation relative to its net income.

Breakdown
Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
7.16M	16.36M	17.26M	8.46M	2.84M
	Gross Profit
-3.14M	-15.55M	-15.66M	-7.42M	-6.41M
	EBIT
-14.36M	-27.34M	-112.12M	-91.33M	-72.57M
	EBITDA
-13.49M	35.20M	-105.12M	-91.33M	-68.12M
	Net Income Common Stockholders
-81.66M	-39.62M	-123.36M	-101.98M	-119.31M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
22.40M	70.45M	100.77M	131.07M	71.80M
	Total Assets
53.96M	133.44M	169.79M	192.53M	105.45M
	Total Debt
38.48M	38.86M	45.40M	41.08M	41.13M
	Net Debt
19.31M	13.27M	21.33M	15.84M	31.68M
	Total Liabilities
54.84M	58.42M	64.07M	65.95M	331.27M
	Stockholders Equity
-879.00K	75.02M	105.73M	126.58M	-225.81M
Cash Flow		Free Cash Flow
-63.34M	-89.02M	-109.66M	-96.39M	-69.38M
	Operating Cash Flow
-63.12M	-85.03M	-99.68M	-85.17M	-55.99M
	Investing Cash Flow
58.55M	104.75M	19.07M	-63.82M	-70.43M
	Financing Cash Flow
-2.66M	-12.12M	79.57M	164.43M	126.34M

Acutus Medical Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.04
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AFIB, the sentiment is Neutral. The current price of 0.04 is above the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.04, and below the 200-day MA of 0.06, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 51.06 is Neutral, neither overbought nor oversold. The STOCH value of 82.89 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AFIB.

Acutus Medical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CLPT	61 Neutral	$403.75M	―	-81.24%	―	31.04%	22.18%
Sector *	52 Neutral	$5.24B	3.76	-41.88%	2.85%	17.01%	0.78%
AXGN	51 Neutral	$747.23M	―	-9.99%	―	17.81%	54.69%
NUWE	48 Neutral	$4.64M	―	-229.24%	―	-1.40%	91.79%
BMRA	45 Neutral	$8.40M	―	-72.70%	―	5.05%	26.13%
SINT	42 Neutral	$6.77M	―	-174.07%	―	9.90%	94.56%
AFIB	40 Underperform	$1.23M	―	406.89%	―	―	―

Acutus Medical Corporate Events

Acutus Medical Restructures Workforce Amid Strategic Shift

Acutus Medical has announced a significant downsizing, reducing its workforce by 70% to focus solely on fulfilling obligations to Medtronic for left-heart access products. This strategic move aims to cut costs while leveraging potential earnout payments from Medtronic until 2027. The transition will include operational changes and a shift in CEO and CFO roles, with the company continuing to support Medtronic through contract manufacturing. The downsizing is expected to be largely complete by Q1 2025.